Lead Product(s): Imlifidase
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: $407.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement July 02, 2020
Hansa Biopharma Granted Sarepta an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD).